DrugPatentWatch Database Preview

Drugs in Development Information for Beloranib

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Beloranib?

Beloranib is an investigational drug.

There have been 8 clinical trials for Beloranib. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1^st 2014.

The most common disease conditions in clinical trials are Prader-Willi Syndrome, Overweight, and Obesity. The leading clinical trial sponsors are Zafgen, Inc. and [disabled in preview].

There are seventy-four US patents protecting this investigational drug and eight hundred and sixteen international patents.

Summary for Beloranib

US Patents	74
International Patents	816
US Patent Applications	148
WIPO Patent Applications	87
Japanese Patent Applications	45
Clinical Trial Progress	Phase 2 (2014-09-01)
Vendors	13

Recent Clinical Trials for Beloranib

Title	Sponsor	Phase
An Efficacy and Safety Study of Beloranib in Obese Subjects With Type 2 Diabetes Mellitus	Zafgen, Inc.	Phase 2
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome	Zafgen, Inc.	Phase 3
An Efficacy, Safety, and Pharmacokinetics Study of Beloranib in Obese Subjects With Hypothalamic Injury	Zafgen, Inc.	Phase 2

See all Beloranib clinical trials

Clinical Trial Summary for Beloranib

Top disease conditions for Beloranib

Top clinical trial sponsors for Beloranib

See all Beloranib clinical trials

US Patents for Beloranib

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
Beloranib		METAP2 inhibitors and methods of treating obesity	SynDevRx, Inc. (Cambridge, MA)
Beloranib		Glial cell line derived neurotrophic factor, obesity, and obesity-related diseases and conditions	Emory University (Atlanta, GA) The United States Geovernment represented by the United States Department of Veterans Affairs (Washington, DC)
Beloranib		Methods for treating subjects with prader-willi syndrome or smith-magenis syndrome	Essentialis, Inc. (Redwood City, CA)
Beloranib		Anti-Laminin4 antibodies specific for LG4-5	PROTHENA BIOSCIENCES LIMITED (Dublin, IE)
Beloranib		Controlled release dosage form	TRIASTEK, INC. (Nanjing, CN)
Beloranib		Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk	ELCELYX THERAPEUTICS, INC. (San Diego, CA)
Beloranib		ACC inhibitors and uses thereof	Gilead Apollo, LLC (Foster City, CA)

International Patents for Beloranib

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
Beloranib	Argentina	AR095828	2033-04-10
Beloranib	Australia	AU2014250983	2033-04-10
Beloranib	Brazil	BR112015025892	2033-04-10
Beloranib	Canada	CA2908993	2033-04-10
Beloranib	China	CN105431426	2033-04-10
Beloranib	Denmark	DK2984085	2033-04-10
Beloranib	Eurasian Patent Organization	EA033912	2033-04-10